following an abbreviated submission:
etrasimod (Velsipity®) is accepted for use within NHSScotland.
Indication under review: for the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
Etrasimod offers an additional treatment choice in the therapeutic class of sphingosine 1-phosphate (S1P) receptor modulators.
This advice applies only in the context of approved NHSScotland Patient Access Scheme (PAS) arrangements delivering the cost-effectiveness results upon which the decision was based, or PAS/ list prices that are equivalent or lower.
Download detailed advice267KB (PDF)
Medicine details
- Medicine name:
- etrasimod (Velsipity
- SMC ID:
- SMC2655
- Indication:
For the treatment of patients 16 years of age and older with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy, or a biological agent.
- Pharmaceutical company
- Pfizer Ltd
- BNF chapter
- Gastro-intestinal system
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 10 June 2024